RTSNRetension Pharmaceuticals, Inc.

🇺🇸 US
12.01
USD
Analysis Scores
Lothien Robustness Score?
16/100
Very Weak
Neden bu skor?
Damodaran ?
0/100
DCF hesaplanamadı (faaliyet kârı veya nakit akışı eksik)
Dalio Risk ?
54/100
Piotroski ?
1/9
Weak
Önceki yıl borç/varlık verisi yok → kaldıraç azalması kontrol edilemedi (C5); gross profit, revenue, prev year gross profit data missing → margin comparison unavailable (C8)
Graham ?
Veri Yetersiz
Özkaynaklar negatif veya sıfır — Graham formülü pozitif defter değeri gerektirir
Lothien Robustness Summary
29/100
Lothien Sağlamlık: Çok Zayıf (29/100)
Temel göstergelerin çoğu olumsuz. Lothien sağlamlık skoru düşük seviyede. | Kısa Vade: Nötr | Uzun Vade: Nötr | Pozitif: 1 | Negatif: 4 | Nötr: 1
Net Zarar
Son çeyrekte -$2M zarar açıklandı. Yatırımcı dikkatli olmalı.
Kâr Stabil
Net kâr bir önceki çeyreğe göre fazla değişmedi (%+0.0). İstikrarlı seyir.
Yıllık Kâr Geriledi
Geçen yılın aynı dönemine göre net kâr %-230.0 düştü. Uzun vadede endişe verici.
Güçlü Likidite
Cari oran 23.51x — kısa vadeli borçları rahat karşılıyor.
Lothien Sağlamlık Skoru: 16/100
Bileşik algoritma değerlendirmesine göre şirketin finansal yapısı zayıf görünüyor.
Sonraki Çeyrek: Düşüş Beklentisi
Tahminine göre kâr %-28.8 düşebilir. Sonraki bilançoya dikkat.

Data date 2026-11-13 Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date 2026-11-13
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Valuation
Potential?
-
ROIC ?
-41.0%
Debt Cycle?
Geç Genişleme
Balance Sheet Analysis? Q2026/9
Son 5 çeyrek ardışık zarar
Fiyat TRAMA-99 hafif altında: %+0.0
Direnç seviyesi: TRAMA-99 = 12.01 USD
Fundamental & Technical Analysis
Profitability
ROE - Return on Equity (TTM) %20.2
ROE %20.2 — high return on equity.
Valuation
No sector data
Indebtedness
Current Ratio 5.61x
Current ratio 5.61x — current assets are 2x short-term liabilities. Very healthy liquidity.
Interest Coverage -3.8x
Interest coverage -3.8x — critical level. Risk of difficulty in interest payments.
Growth
Net Profit Growth (YoY) %-230.0
Loss %230.0 increased — losses deepening.
Score Explanations
Lothien Robustness
16/100
Very weak robustness (16/100). Multiple critical indicators are red: high debt, low profitability or excessive valuation.
Very Weak
Damodaran Valuation
0/100
Very Weak
Dalio Risk Analysis
54/100
Moderate debt risk (54/100). Interest coverage ratio -3.8x — weak, fragile.
Leverage: 50/100 | Debt Service: 100/100 | Quality: 40/100
ROIC - Return on Capital
%-41.0
ROIC (%-41.0) cost of capital (11.9%) below → destroying value.
WACC: %11.9
Debt Cycle Phase
Geç Genişleme
Piotroski F-Score
1/9
Weak
Graham Intrinsic Value
—
⚖️ Sector Comparison
ROIC vs WACC
%-41.0 vs %11.9 WACC
ROIC 52.9 bps below cost of capital
↔
TRAMA-99 Trend — Near TRAMA
Price (12.01), TRAMA-99 line (12.01) at close levels (%+0.0). Important decision zone — breakout direction will determine the trend.
Price:: 12.01
TRAMA: 12.01
Difference: %+0.0
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
▲ içeriden alım · ▼ içeriden satım · ★ katalizör (haber-sezgisel) · ■ 13D aktivist · ■ 13G pasif — SEC Form 4 ~2 gün gecikmeli, yalnız yönetici/direktör/%10+ sahip; katalizör = haber-sezgisel; 13D/G = %5+ pay bildirimi ~5 iş günü gecikmeli.
RSI (14) ?
Bollinger Bands ?
MACD ?

İçeriden Alım-Satım Akışı

Kim aldı, kim sattı, ne kadar

RTSN — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.